Related Experiment Videos
Nitrosoureas in the management of disseminated malignant melanoma
Abstract:
Three of the nitrosoureas, BCNU, CCNU, and methyl-CCNU, have displayed significant antitumor activity in patients with disseminated malignant melanoma with none clearly superior to the others, although direct comparison in clinical trials was not accomplished. Response rates to various combinations of these nitrosoureas seem a bit higher, but not dramatically so, when compared to the single-agent response rates, although again this cannot be stated with certainty since direct comparisons were not accomplished. There appears to be no therapeutic advantage to the utilization of any one of the nitrosoureas over the others, but oral administration, as is available for CCNU and methyl-CCNU, is a distinct advantage to the patient and to the clinician. The response rates are, for the most part, rather consistent for the various studies reported in this paper, and these response rates leave a great deal of room for improvement. Secondary therapy utilizing the nitrosoureas was singularly unsuccessful in most of the reported clinical trials. It is refreshing, however, to have agents which have shown activity, although modest, in this most refractory of neoplasms.
Insights
Carmustine (BCNU), lomustine (CCNU), and methyl-CCNU show antitumor activity in malignant melanoma. Oral administration offers a patient advantage, though overall efficacy requires improvement.
Area of Science:
- Oncology
- Pharmacology
Background:
- Malignant melanoma is a refractory neoplasm with limited treatment options.
- Nitrosoureas have demonstrated antitumor activity in this disease.
Purpose of the Study:
- To review the efficacy of nitrosoureas (BCNU, CCNU, methyl-CCNU) in disseminated malignant melanoma.
- To assess the comparative effectiveness and administration advantages of these agents.
Main Methods:
- Review of clinical trial data on nitrosourea monotherapy and combination therapy.
- Analysis of response rates and therapeutic advantages.
Main Results:
- BCNU, CCNU, and methyl-CCNU show significant antitumor activity, with no single agent clearly superior.
- Combination therapy may offer slightly higher response rates, but not dramatically.
- Oral administration of CCNU and methyl-CCNU provides a practical advantage.
- Response rates are consistent but indicate room for improvement.
- Secondary nitrosourea therapy showed limited success.
Conclusions:
- Nitrosoureas are valuable agents for malignant melanoma, despite modest efficacy.
- Oral administration is a key benefit for CCNU and methyl-CCNU.
- Further research is needed to enhance treatment outcomes for this difficult cancer.